Summary The monoclonal anti-CEA antibody, A5B7, has previously been administered to patients for radioimmunotherapy (RIT). Long circulation time and the formation of an immune response have limited therapeutic success in the clinic. Antibody fragments can be used to reduce the in vivo circulation time, but the best combination of fragment and radioisotope to use for therapy is far from clear. In this study we have compared the biodistribution of A5B7 IgG and F(ab')2 with chemically cross-linked divalent (DFM) and trivalent (TFM) A5B7 Fab' fragments in nude mice bearing human colorectal tumour xenografts. The crosslinkers were designed to allow site-specific labelling using yttrium 90 (90Y), a high-energy f-emitter. We have also compared the above antibody forms conjugated to both 13'I and 9'Y. Both DFM and TFM were fully immunoreactive and remained intact after radiolabelling and incubation in serum at 37°C for 24 h. Biodistribution results showed similar tumour uptake levels and an identical blood clearance pattern for F(ab')2 and DFM with high tumour-blood ratios generated in each case. However, unacceptably high kidney accumulation for both F(ab')2 and DFM and elevated splenic uptake of DFM labelled with 9'Y was observed.
The use of antibodies to deliver radiation selectively to tumours for therapeutic and diagnostic purposes is now well established (Waldmann, 1991; Jurcic and Scheinberg., 1994; Larson et al., 1994) . The murine A5B7 antibody raised against carcinoembryonic antigen (CEA) has been used for both imaging and therapy in nude mice bearing human colorectal tumour xenografts (Pedley et al., 1993) and in patients (Lane et al., 1994) . However, results from clinical trials using this antibody, and many other studies on the treatment of solid tumours, have been disappointing, considering the success in mice (Begent and Pedley, 1990; Delaloye and Delaloye, 1995) . In spite of this, some patient responses to radioimmunotherapy (RIT) have been reported (Begent and Pedley, 1990; Lane et al., 1994) , suggesting that improvements to current methodology may be clinically beneficial.
There are a number of factors thought to influence antibody localisation to the tumour, which may account for the wide variation in tumour uptake levels between patients (Boxer et al., 1992) . These include heterogeneous expression of antigen, variable levels of antibody achieved in the blood, the presence of circulating antigen, tumour vascularisation and the penetration of antibody into tumour tissue. In addition, RIT is often limited by the toxicity of circulating activity, particularly to the bone marrow. In attempts to overcome these problems, several strategies have been attempted to improve the delivery to tumours, while removing circulating radiolabelled antibody more rapidly, in order to reduce the dose to the bone marrow. These include the use of specific clearing regimens either in vivo or ex vivo (Begent et al., 1987; Norrgren et al., 1993) , the use of twostep targeting regimens (Goodwin et al., 1994) and the use of antibody fragments.
F(ab')2 fragments have been widely investigated for RIT, both in animal models and in the clinic (Lane et al., 1994) . It has been shown that, in some situations, F(ab') fragments may be more suitable for RIT than intact IgG labelled with 131I (Buchegger et al., 1990; Yorke et al., 1991) . However, comparatively few studies have attempted to identify the most suitable fragments for RIT with different isotopes. Small antibody fragments such as Fv and single-chain Fv (scFv) fragments showed improved penetration into tumour tissue . ScFv fragments also show favourable tumour-blood ratios and are potentially excellent reagents for tumour imaging (Chester et al., 1994) . However, the dose of antibody delivered to the tumour by these rapidly cleared fragments is relatively low and further development is required before a therapeutic tumour dose could be delivered. We have been evaluating alternative reagents comprising multivalent Fab's produced by chemical cross-linking. Chemically cross-linked di-Fab (DFM) and tri-Fab (TFM) have been prepared from the mouse-human chimeric Fab' fragment of B72.3 (King et al., 1994) and an engineered human form of the antibody (King et al., 1995) . Biodistribution studies with these antibodies have revealed higher tumour accumulation than seen with scFvs, although clearance from the blood is still rapid. In addition, the choice of antibody fragment for RIT may be different for different isotopes. It is well known that the biodistribution of antibody fragments labelled with radioiodine is very different from those labelled with metallic radionuclides such as . '.In, 90Y, '77Lu, 67Cu and 99'Tc (Brown et al., 1987; Sharkey et al., 1990; Schott et al., 1992) . The purpose of this study was, therefore, to determine which was the optimal form of the antibody A5B7 for RIT with the isotopes 131I and 90Y. Kinetic analysis was carried out by surface plasmon resonance using the BlAcore system (Pharmacia Biosensor) to measure on and off rates of the above antibodies. CEA antigen was immobilised to biosensor chips using surface thiol chemistry or, alternatively, by aldehyde chemistry, and the immobilised antigen density was optimised in a similar way to that described previously (Abraham et al., 1995) . Kinetic binding parameters were calculated using BIA evaluation software after correcting concentrations to nm binding sites (assuming two binding sites per antibody for IgG, F(ab')2 and DFM, three for TFM and one binding site for F(ab'), such that antibody forms with different numbers of binding sites could be compared.
Radiolabelling and animal studies Labelling with 1311 was performed using the chloramine T method. Free iodine was removed using a PD-10 column blocked with 3% BSA and equilibrated in PBS, and percentage incorporation of radiolabel was analysed by thin-layer chromatography (TLC) analysis in 80% methanol.
Antibodies for 90Y labelling were first desalted into 0.1 M MES buffer, pH 6.0, at concentrations > 1 mg ml-'. 90Yttrium chloride (9OYCI3, Amersham) at 50 mCi ml-' was added to achieve a specific activity of 2 pCi pg-' and w 1399 incubated for 20 min at room temperature. The reaction was quenched by addition of 10 mM DTPA for 10 min at room temperature. Incorporation was measured by TLC in a mobile phase of 0.1 M citrate buffer, pH 5.0, and HPLC gel filtration was used to remove any unreacted 90Y. Characterisation of antibodies after labelling was performed to ensure full immunoreactivity by applying a dilution of the radiolabelled antibody to a 1 ml CEA affinity column and measuring the percentage bound, as described previously by Casey et al. (1995) . Stability of radiolabelled antibody was analysed by application of an aliquot of the sample to a Sephacryl S-300 column (110 x 1 cm). Fractions (1.3 ml) were monitored for 131I or 90Y levels. Stability at 37°C in human serum for 24 h was also assessed.
Comparative biodistribution experiments were performed in the nude mouse colorectal xenograft model, LS 1 74T (Pedley et al., 1993) .
Results
Preparation of F(ab')2, DFM and TFM Digestion of A5B7 with bromelain enzyme routinely produced approximately 70% fully immunoreactive F(ab')2 in 1 h. Purification of this F(ab')2 resulted in material which was >90% pure as assessed by SDS-PAGE (Figure 1 ). Cross-linking of Fab' to DFM was monitored by HPLC gel filtration after a 2 h incubation period and resulted in yields of approximately 40% cross-linked dimer with less than 5% reoxidised F(ab')2. For TFM cross-linking, yields of approximately 25% cross-linked trimer were obtained. These yields are relatively low compared with those obtained previously with recombinant antibody fragments, where yields of 70% (DFM) and 60% (TFM) have been observed . This is probably a result of using murine A5B7 Fab', which contains three hinge cysteine residues compared with recombinant Fab', which has a single hinge thiol residue. Optimisation studies have shown that higher cross-linking levels may be achieved on a larger scale at higher antibody concentrations. DFM and TFM were purified by HPLC gel filtration to >90% purity as illustrated by SDS-PAGE analysis in Figure 1 .
Antigen binding and kinetic analysis
Antigen binding analysis by ELISA demonstrated full reactivity of DFM and F(ab')2-macrocycle conjugate compared with that of native F(ab')2 (Figure 2a) . DFM also showed slightly higher binding than F(ab')2 and the F(ab')2-macrocycle conjugate. TFM and IgG-macrocycle retained full reactivity ( Figure 2b ) compared with unmodified IgG, and TFM also demonstrated a slightly higher binding than IgG and the macrocycle conjugate. It was important to analyse the immunoreactivity of antibody after modification, as high levels of reducing agent or 2-iminothiolane have been reported to cause loss of immunoreactivity or aggregation .
Kinetic analysis of antigen binding was performed using surface plasmon resonance with a BlAcore instrument (Pharmacia Biosensor). The amount of CEA coupled to the sensor chip was optimised in preliminary experiments using either PDEA surface thiol or aldehyde immobilisation. The optimal antigen binding density for kinetic analysis was determined at which the antibody-antigen interaction was minimal for mass transport (768 RU for aldehyde coupling and 2544 RU for surface thiol immobilisation of CEA). Table I Table I . This probably reflects the fact that the antigen density was significantly higher for the thiol-immobilised surface allowing more rebinding events to occur during the dissociation phase than with the alternative surface.
Radiolabelling and stability TLC analysis of radiolabelled antibodies routinely revealed 96-99% incorporation of 131I and 90Y after purification. Antigen binding by application of a small sample of radiolabelled antibody to a 1 ml CEA affinity column revealed retention of 90-96% binding. A non-CEA antibody was radiolabelled as a control and 2-10% total activity bound to the column.
Antibodies after labelling and incubation at 37°C in normal human serum remained intact and non-aggregated, as shown in Figure 3 by S-300 gel filtration chromatography.
Biodistribution study The biodistribution of A5B7 F(ab')2 and DFM, and also A5B7 IgG and TFM were compared in tumour-bearing mice over a 6 day period after radiolabelling with both 131I and Figure 4a and b) proved to be very similar, suggesting there is no significant difference in the stability of these fragments in vivo. Rapid clearance from the blood and normal tissues by 24 h produced high therapeutic tumour-blood ratios illustrated in Table 11 (38:1 F(ab')2; 26:1 DFM), which were retained over the 6 day period. Labelling with 90Y dramatically altered the biodistribution (Figure 4c and d) leading to very high accumulation in the kidney at early time points and throughout the 6 days, producing a very different clearance pattern to the iodinated fragments. High splenic uptake was also observed, which accumulated over time, especially for DFM (144 h: F(ab')2 8.5%; DFM 20%). Despite unfavourable uptake in the kidney and spleen, tumour uptake levels were similar to the iodinated fragments IgG and TFM The blood clearance of TFM, despite its similar size (150 kDa), was significantly faster than IgG (P<0.02, using the Mann-Whitney U-test non-parametric statistical analysis) as illustrated in Figure 5 . This produced superior therapeutic tumour-blood ratios (Table II) Figure Sc and d) ; this persisted over time and was most apparent at later time points, e.g. at 48 h: "3'I (IgG 15% ID g-'; TFM 10% ID g-'), 9Y (IgG 25% ID g-1; TFM 17% ID g '). This may be caused by higher retention of yttrium-labelled conjugates in cells compared with iodinated conjugates that are dehalogenated. The levels of radiolabel in the tumour for IgG and TFM were also greater than for F(ab')2 and DFM fragments, probably as a result of slower clearance from the circulation. However, the lower molecular weight fragments produced high therapeutic ratios earlier, potentially reducing toxicity and, thus, allowing larger doses to be given. In contrast to 90Y-labelled DFM and F(ab')2, kidney uptake levels of both However, despite these potential benefits of using F(ab')2 fragments, the lack of the Fc portion exposes the hinge regoin, making it more susceptible to enzymatic and/or reductive breakdown. In addition, different F(ab')2 fragments have different in vivo stabilities. For example, in a study comparing murine F(ab')2 from an IgG1 antibody with chimeric F(ab')2 of human subclasses 1, 2 and 4, it was reported that human IgG4 F(ab')2 fragments were relatively unstable in vivo, human IgG2 the most stable and murine IgG1 and human IgG1 F(ab')2 of intermediate stability (Buchegger et al., 1992) . Chemically cross-linked F(ab')2 fragments and trispecific F(ab')3 derivatives have been produced through use of bis-maleimide linkers using techniques developed by Glennie et al. (1987) and Tutt et al. (1991) . Recombinant Fab's have also been synthesised with a single hinge thiol to facilitate cross-linking reactions (Carter et al., 1992; King et al., 1994) and scFv molecules with a C-terminal cysteine expressed, which allow crosslinking (Cumber et al., 1992) . In some reports, increased in vivo stability of the cross-linked fragments has been demonstrated (Quadri et al., 1993; King et al., 1994 The major site of antibody fragment catabolism in mice is the kidneys (Covell et al., 1986) and this was the normal organ with the highest level of 1311 and [9rY]F(ab')2 and DFM at early time points. Radioiodinated fragments undergo metabolism to release low molecular weight fragments, which are rapidly released from cells and cleared (Press et al., 1990) , whereas radiometals are retained longer owing to cellular trapping of the chelate (Pimm et al., 1989) . Biodistribution of antibody fragments labelled with 131I and "'In have been compared previously (Andrew et al., 1988) . For "'In-labelled F(ab')2 >60% of administered activity was retained in the kidneys compared with <10% for ['31I]F(ab')2. This is similar to the difference we observe here for 90Y-labelled F(ab')2 and DFM; kidney-blood ratios are increased 3-fold at 3 h and over 100-fold at 24 h compared with "3'1-labelled fragments.
The stability of the attachment of radiochelate to antibody is an important determinant of therapeutic ratio, since some labelling methods, involving derivatives of the chelating ligand DTPA, produce relatively labile conjugates in vivo (Harrison et al., 1991) . Weak ligands will lead to both a reduction in the amount of 90Y-conjugate in the tumour and irradiation of the normal tissues with free 90Y, especially proliferating tissues of the bone marrow, since 90Y is a boneseeking isotope (Hnatowich et al., 1983) . The development of new chelating agents, such as the macrocyclic chelating agent DOTA (Moi et al., 1988; Cox et al., 1989) , have proved to be more stable in vivo (Hird et al., 1991; Harrison et al., 1991) . The cross-linkers used in this study contain the 12N4 DOTA macrocycle, which allows the site-specific attachment of 90Y and this has the added advantage that there is no loss of antigen binding after radiolabelling. Attachment of radiolabel in random positions, as we describe here for IgG and F(ab')2, leads to non-homogenous preparations owing to variation in the number of thiol groups generated, and may reduce immunoreactivity, if residues which contribute to antigen binding are modified.
Engineering In contrast to the divalent fragments, kidney accumulation was greatly reduced. This is presumably mainly due to the increase in molecular weight, although the slight increase in kidney levels of TFM compared with IgG suggest that there may be other factors, such as shape and charge, which also influence the filtration process (Sumpio and Hayslett, 1985 
